1 / 34

Patient-Centered Care in Advanced Bladder Cancer

Patient-Centered Care in Advanced Bladder Cancer. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Introduction. Case 1 A 68-Year-Old Man. Cisplatin-Based Chemotherapy.

bernad
Download Presentation

Patient-Centered Care in Advanced Bladder Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Patient-Centered Care in Advanced Bladder Cancer

  2. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

  3. Introduction

  4. Case 1A 68-Year-Old Man

  5. Cisplatin-Based Chemotherapy

  6. Determining Platinum Eligibility

  7. Case (cont)

  8. Carboplatin + Gemcitabine

  9. Atezolizumab

  10. Pembrolizumab

  11. Potential Advantages of the Options

  12. PD-L1 Testing

  13. Case (cont)

  14. More Factors to Consider When Choosing Treatment

  15. Case (cont)

  16. Pseudoprogression

  17. Treating After Progression on a Checkpoint Inhibitor

  18. Case 2A 78-Year-Old Man

  19. Treatment Options

  20. Checkpoint Inhibition Trials in the Second-Line Setting

  21. Phase 3 Trials

  22. Evaluating IMvigor 211

  23. PD-L1 Testing in the Second-Line Setting

  24. Patient Education

  25. Case (cont)

  26. Management of Diarrhea/Colitis

  27. Case Conclusion

  28. Biomarkers for Immunotherapy

  29. Combination Therapies

  30. Progression Following Chemotherapy and Checkpoint Inhibition

  31. Concluding Remarks

  32. Abbreviations

  33. Abbreviations (cont)

More Related